FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100041732> ?p ?o ?g. }

• W2100041732 endingPage "1605" @default.
• W2100041732 startingPage "1598" @default.
• W2100041732 abstract "ObjectiveThis study evaluated outcomes of remote endarterectomy (RE) vs endovascular (ENDO) interventions on TransAtlantic Inter-Societal Consensus (TASC)-II D femoropopliteal lesions and identified factors predictive of restenosis.MethodsFrom October 2004 to December 2008, 95 patients with TASC-II D lesions were randomized 1:1 to receive RE of the superficial femoral artery (SFA) with end point stenting (51 patients) or ENDO, consisting of subintimal angioplasty with stenting (44 patients). The groups were balanced for age, sex, atherosclerotic risk factors, and comorbidities. Categoric data were analyzed with χ2 tests, and time to event provided two-sided P values with a level of significance at .05 and 95% confidence intervals (CIs). Survival curves for primary patency were plotted using the Kaplan-Meier method. Univariate analysis for diabetes, hypertension, dyslipidemia, smoking, and critical ischemia was performed according to the Cox proportional hazards model.ResultsThe mean follow-up was 52.5 months (range, 35-75 months). Five RE patients and four ENDO patients were lost to follow-up (censored). Primary patency was 76.5% (39 of 51) in RE and 56.8% (25 of 44) in ENDO (hazard ratio [HR], 2.6; 95% CI, 0.99-4.2; P = .05) at 24 months and was 62.7% (32 of 46) in RE and 47.7% (21 of 40) in ENDO (HR, 1.89; 95% CI, 0.94-3.78; P = .07) at 36 months. Assisted primary patency was 70.6% (36 of 51) in RE and 52.3% (23 of 44) in ENDO (HR, 2.45; 95% CI, 1.20-5.02; P = .01). Secondary patency overlapped the primary comparison data at 12 and 24 months; at 36 months, there was a slight but significative advantage for RE (HR, 2.26; 95% CI, 1.05-4.86; P = .03). Univariate analysis demonstrated that hypercholesterolemia and critical limb ischemia (CLI) were significantly related to patency failure, whereas diabetes was significant only in ENDO. These factors (hypercholesterolemia and CLI) were independent predictors of patency on Cox multivariate analysis.ConclusionsRE is a safe, effective, and durable procedure for TASC-II D lesions. Our data demonstrate a significantly higher primary, assisted primary, and secondary patency of RE vs ENDO procedures. Furthermore, overall secondary patency rates remain within the standard limits, although preoperative CLI and dyslipidemia continue to be associated with worse outcomes. Taken together, these data suggest that RE should be considered better than an endovascular procedure in SFA long-segment occlusion treatment. This study evaluated outcomes of remote endarterectomy (RE) vs endovascular (ENDO) interventions on TransAtlantic Inter-Societal Consensus (TASC)-II D femoropopliteal lesions and identified factors predictive of restenosis. From October 2004 to December 2008, 95 patients with TASC-II D lesions were randomized 1:1 to receive RE of the superficial femoral artery (SFA) with end point stenting (51 patients) or ENDO, consisting of subintimal angioplasty with stenting (44 patients). The groups were balanced for age, sex, atherosclerotic risk factors, and comorbidities. Categoric data were analyzed with χ2 tests, and time to event provided two-sided P values with a level of significance at .05 and 95% confidence intervals (CIs). Survival curves for primary patency were plotted using the Kaplan-Meier method. Univariate analysis for diabetes, hypertension, dyslipidemia, smoking, and critical ischemia was performed according to the Cox proportional hazards model. The mean follow-up was 52.5 months (range, 35-75 months). Five RE patients and four ENDO patients were lost to follow-up (censored). Primary patency was 76.5% (39 of 51) in RE and 56.8% (25 of 44) in ENDO (hazard ratio [HR], 2.6; 95% CI, 0.99-4.2; P = .05) at 24 months and was 62.7% (32 of 46) in RE and 47.7% (21 of 40) in ENDO (HR, 1.89; 95% CI, 0.94-3.78; P = .07) at 36 months. Assisted primary patency was 70.6% (36 of 51) in RE and 52.3% (23 of 44) in ENDO (HR, 2.45; 95% CI, 1.20-5.02; P = .01). Secondary patency overlapped the primary comparison data at 12 and 24 months; at 36 months, there was a slight but significative advantage for RE (HR, 2.26; 95% CI, 1.05-4.86; P = .03). Univariate analysis demonstrated that hypercholesterolemia and critical limb ischemia (CLI) were significantly related to patency failure, whereas diabetes was significant only in ENDO. These factors (hypercholesterolemia and CLI) were independent predictors of patency on Cox multivariate analysis. RE is a safe, effective, and durable procedure for TASC-II D lesions. Our data demonstrate a significantly higher primary, assisted primary, and secondary patency of RE vs ENDO procedures. Furthermore, overall secondary patency rates remain within the standard limits, although preoperative CLI and dyslipidemia continue to be associated with worse outcomes. Taken together, these data suggest that RE should be considered better than an endovascular procedure in SFA long-segment occlusion treatment." @default.
• W2100041732 created "2016-06-24" @default.
• W2100041732 creator A5015076472 @default.
• W2100041732 creator A5024159122 @default.
• W2100041732 creator A5041195117 @default.
• W2100041732 creator A5042176712 @default.
• W2100041732 creator A5045129892 @default.
• W2100041732 creator A5064376976 @default.
• W2100041732 creator A5071292295 @default.
• W2100041732 creator A5080167911 @default.
• W2100041732 date "2012-12-01" @default.
• W2100041732 modified "2023-10-17" @default.
• W2100041732 title "Randomized controlled trial of remote endarterectomy versus endovascular intervention for TransAtlantic Inter-Society Consensus II D femoropopliteal lesions" @default.
• W2100041732 cites W1924484409 @default.
• W2100041732 cites W1965054216 @default.
• W2100041732 cites W1967627562 @default.
• W2100041732 cites W1974295559 @default.
• W2100041732 cites W1975134053 @default.
• W2100041732 cites W1980462082 @default.
• W2100041732 cites W1983070830 @default.
• W2100041732 cites W2003125517 @default.
• W2100041732 cites W2009254740 @default.
• W2100041732 cites W2016594382 @default.
• W2100041732 cites W2026481871 @default.
• W2100041732 cites W2027163052 @default.
• W2100041732 cites W2033508513 @default.
• W2100041732 cites W2035885604 @default.
• W2100041732 cites W2043517681 @default.
• W2100041732 cites W2050116050 @default.
• W2100041732 cites W2055307720 @default.
• W2100041732 cites W2069424077 @default.
• W2100041732 cites W2070728506 @default.
• W2100041732 cites W2082142222 @default.
• W2100041732 cites W2094550790 @default.
• W2100041732 cites W2100334547 @default.
• W2100041732 cites W2106119472 @default.
• W2100041732 cites W2124283000 @default.
• W2100041732 cites W2144985796 @default.
• W2100041732 cites W2145994607 @default.
• W2100041732 cites W2153683974 @default.
• W2100041732 cites W2169363662 @default.
• W2100041732 cites W2170618568 @default.
• W2100041732 cites W2346635422 @default.
• W2100041732 cites W2569906950 @default.
• W2100041732 cites W4245284657 @default.
• W2100041732 doi "https://doi.org/10.1016/j.jvs.2012.06.081" @default.
• W2100041732 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23044257" @default.
• W2100041732 hasPublicationYear "2012" @default.
• W2100041732 type Work @default.
• W2100041732 sameAs 2100041732 @default.
• W2100041732 citedByCount "28" @default.
• W2100041732 countsByYear W21000417322013 @default.
• W2100041732 countsByYear W21000417322014 @default.
• W2100041732 countsByYear W21000417322015 @default.
• W2100041732 countsByYear W21000417322016 @default.
• W2100041732 countsByYear W21000417322017 @default.
• W2100041732 countsByYear W21000417322018 @default.
• W2100041732 countsByYear W21000417322019 @default.
• W2100041732 countsByYear W21000417322020 @default.
• W2100041732 countsByYear W21000417322021 @default.
• W2100041732 countsByYear W21000417322022 @default.
• W2100041732 countsByYear W21000417322023 @default.
• W2100041732 crossrefType "journal-article" @default.
• W2100041732 hasAuthorship W2100041732A5015076472 @default.
• W2100041732 hasAuthorship W2100041732A5024159122 @default.
• W2100041732 hasAuthorship W2100041732A5041195117 @default.
• W2100041732 hasAuthorship W2100041732A5042176712 @default.
• W2100041732 hasAuthorship W2100041732A5045129892 @default.
• W2100041732 hasAuthorship W2100041732A5064376976 @default.
• W2100041732 hasAuthorship W2100041732A5071292295 @default.
• W2100041732 hasAuthorship W2100041732A5080167911 @default.
• W2100041732 hasBestOaLocation W21000417321 @default.
• W2100041732 hasConcept C126322002 @default.
• W2100041732 hasConcept C141071460 @default.
• W2100041732 hasConcept C168563851 @default.
• W2100041732 hasConcept C207103383 @default.
• W2100041732 hasConcept C2778096610 @default.
• W2100041732 hasConcept C2778283817 @default.
• W2100041732 hasConcept C2778583881 @default.
• W2100041732 hasConcept C2779745121 @default.
• W2100041732 hasConcept C2780007028 @default.
• W2100041732 hasConcept C2780326628 @default.
• W2100041732 hasConcept C44249647 @default.
• W2100041732 hasConcept C511355011 @default.
• W2100041732 hasConcept C71924100 @default.
• W2100041732 hasConceptScore W2100041732C126322002 @default.
• W2100041732 hasConceptScore W2100041732C141071460 @default.
• W2100041732 hasConceptScore W2100041732C168563851 @default.
• W2100041732 hasConceptScore W2100041732C207103383 @default.
• W2100041732 hasConceptScore W2100041732C2778096610 @default.
• W2100041732 hasConceptScore W2100041732C2778283817 @default.
• W2100041732 hasConceptScore W2100041732C2778583881 @default.
• W2100041732 hasConceptScore W2100041732C2779745121 @default.
• W2100041732 hasConceptScore W2100041732C2780007028 @default.
• W2100041732 hasConceptScore W2100041732C2780326628 @default.
• W2100041732 hasConceptScore W2100041732C44249647 @default.
• W2100041732 hasConceptScore W2100041732C511355011 @default.
• W2100041732 hasConceptScore W2100041732C71924100 @default.

• next